Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
LENSAR, Inc. stock logo
LNSR
LENSAR
$3.43
+5.2%
$3.85
$1.80
$5.30
$39.10M0.4739,726 shs44,877 shs
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
$0.06
-12.8%
$0.08
$0.05
$1.25
$2.29M-0.0681,518 shs82,647 shs
PAVmed Inc. stock logo
PAVM
PAVmed
$1.77
-4.3%
$2.19
$1.60
$9.00
$16.23M0.8565,307 shs62,870 shs
Titan Medical Inc. stock logo
TMDI
Titan Medical
$0.14
-26.3%
$0.23
$0.13
$1.20
$15.67M2.364.83 million shs7.71 million shs
Venus Concept Inc. stock logo
VERO
Venus Concept
$0.77
+6.7%
$0.82
$0.60
$4.70
$4.89M0.66447,534 shs21,279 shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
LENSAR, Inc. stock logo
LNSR
LENSAR
+2.52%+6.54%-6.05%-9.44%+25.38%
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
-9.72%-14.47%-26.09%-27.78%-91.85%
PAVmed Inc. stock logo
PAVM
PAVmed
-1.07%-6.09%-16.29%-25.10%-74.34%
Titan Medical Inc. stock logo
TMDI
Titan Medical
0.00%0.00%0.00%0.00%0.00%
Venus Concept Inc. stock logo
VERO
Venus Concept
-10.69%-6.94%+0.13%-40.42%-75.97%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
LENSAR, Inc. stock logo
LNSR
LENSAR
2.9293 of 5 stars
3.55.00.00.02.62.50.0
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
1.8158 of 5 stars
3.50.00.04.50.61.70.0
PAVmed Inc. stock logo
PAVM
PAVmed
1.874 of 5 stars
3.00.00.04.33.20.80.0
Titan Medical Inc. stock logo
TMDI
Titan Medical
N/AN/AN/AN/AN/AN/AN/AN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
2.068 of 5 stars
0.05.00.00.02.93.30.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
LENSAR, Inc. stock logo
LNSR
LENSAR
3.00
Buy$8.00133.24% Upside
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
3.00
Buy$2.504,309.17% Upside
PAVmed Inc. stock logo
PAVM
PAVmed
2.00
Hold$21.001,086.44% Upside
Titan Medical Inc. stock logo
TMDI
Titan Medical
N/AN/AN/AN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
2.00
HoldN/AN/A

Current Analyst Ratings

Latest TMDI, NMRD, VERO, LNSR, and PAVM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/19/2024
LENSAR, Inc. stock logo
LNSR
LENSAR
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
LENSAR, Inc. stock logo
LNSR
LENSAR
$42.16M0.93N/AN/A$2.97 per share1.15
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
$80K28.60N/AN/A($0.41) per share-0.14
PAVmed Inc. stock logo
PAVM
PAVmed
$2.45M6.62N/AN/A($3.35) per share-0.53
Titan Medical Inc. stock logo
TMDI
Titan Medical
$20.09M0.78N/AN/A$0.32 per share0.44
Venus Concept Inc. stock logo
VERO
Venus Concept
$76.35M0.06N/AN/A($2.43) per share-0.32

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
LENSAR, Inc. stock logo
LNSR
LENSAR
-$14.38M-$1.79N/AN/A-34.11%-40.53%-21.83%5/20/2024 (Estimated)
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
-$14.14M-$0.39N/AN/AN/AN/A-142.69%N/A
PAVmed Inc. stock logo
PAVM
PAVmed
-$64.18M-$9.33N/AN/A-2,617.25%N/A-85.99%5/21/2024 (Estimated)
Titan Medical Inc. stock logo
TMDI
Titan Medical
-$14.86M-$0.19N/AN/AN/A-167.03%-112.15%N/A
Venus Concept Inc. stock logo
VERO
Venus Concept
-$37.25M-$6.85N/AN/AN/A-48.79%N/A-36.21%5/15/2024 (Confirmed)

Latest TMDI, NMRD, VERO, LNSR, and PAVM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2024N/A
Venus Concept Inc. stock logo
VERO
Venus Concept
N/AN/AN/AN/AN/AN/A  
4/1/2024Q4 2023
Venus Concept Inc. stock logo
VERO
Venus Concept
N/A-$2.01-$2.01-$2.01N/A$18.13 million
3/26/2024Q4 2023
PAVmed Inc. stock logo
PAVM
PAVmed
N/A-$1.57-$1.57-$1.16N/A$1.05 million
3/4/202412/31/2023
LENSAR, Inc. stock logo
LNSR
LENSAR
-$0.22-$0.22N/A-$0.35N/A$12.11 million    
2/12/2024Q3 2024
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
N/A-$0.12-$0.12-$0.17N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
LENSAR, Inc. stock logo
LNSR
LENSAR
N/AN/AN/AN/AN/A
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
N/AN/AN/AN/AN/A
PAVmed Inc. stock logo
PAVM
PAVmed
N/AN/AN/AN/AN/A
Titan Medical Inc. stock logo
TMDI
Titan Medical
N/AN/AN/AN/AN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
LENSAR, Inc. stock logo
LNSR
LENSAR
N/A
3.99
2.64
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
N/A
0.19
0.03
PAVmed Inc. stock logo
PAVM
PAVmed
N/A
0.45
0.45
Titan Medical Inc. stock logo
TMDI
Titan Medical
N/A
1.41
1.41
Venus Concept Inc. stock logo
VERO
Venus Concept
N/A
2.13
1.39

Ownership

Institutional Ownership

CompanyInstitutional Ownership
LENSAR, Inc. stock logo
LNSR
LENSAR
40.15%
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
4.41%
PAVmed Inc. stock logo
PAVM
PAVmed
19.93%
Titan Medical Inc. stock logo
TMDI
Titan Medical
3.55%
Venus Concept Inc. stock logo
VERO
Venus Concept
87.41%

Insider Ownership

CompanyInsider Ownership
LENSAR, Inc. stock logo
LNSR
LENSAR
38.52%
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
41.60%
PAVmed Inc. stock logo
PAVM
PAVmed
12.60%
Titan Medical Inc. stock logo
TMDI
Titan Medical
0.02%
Venus Concept Inc. stock logo
VERO
Venus Concept
51.39%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
LENSAR, Inc. stock logo
LNSR
LENSAR
13011.40 million7.01 millionOptionable
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
3640.35 million23.57 millionOptionable
PAVmed Inc. stock logo
PAVM
PAVmed
1079.17 million8.02 millionOptionable
Titan Medical Inc. stock logo
TMDI
Titan Medical
49111.95 million111.93 millionNot Optionable
Venus Concept Inc. stock logo
VERO
Venus Concept
3046.36 million3.09 millionNot Optionable

TMDI, NMRD, VERO, LNSR, and PAVM Headlines

SourceHeadline
Venus Concept Announces Loan Purchase and Completion of First Phase of RefinancingVenus Concept Announces Loan Purchase and Completion of First Phase of Refinancing
finance.yahoo.com - April 24 at 7:48 PM
Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024
globenewswire.com - April 15 at 7:30 AM
Venus Concept Inc.: Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAXVenus Concept Inc.: Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX
finanznachrichten.de - April 9 at 1:29 AM
Venus Concept Announces Approval For Venus Bliss MAX In Israel - Quick FactsVenus Concept Announces Approval For Venus Bliss MAX In Israel - Quick Facts
markets.businessinsider.com - April 8 at 10:21 AM
Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAXVenus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX
globenewswire.com - April 8 at 7:30 AM
Ranking every single MoonSwatch thats ever droppedRanking every single MoonSwatch that's ever dropped
gq-magazine.co.uk - April 3 at 10:37 PM
On heels on Vero Beach, Sebastian growth, Fellsmere population to double in five years?On heels on Vero Beach, Sebastian growth, Fellsmere population to double in five years?
news.yahoo.com - April 3 at 10:37 PM
Venus Concept Announces Australian Regulatory Approval for Venus Versa ProVenus Concept Announces Australian Regulatory Approval for Venus Versa Pro
finance.yahoo.com - April 3 at 7:36 AM
Venus Concept Announces Australian Regulatory Approval for Venus Versa ProVenus Concept Announces Australian Regulatory Approval for Venus Versa Pro
globenewswire.com - April 3 at 7:30 AM
Venus Concept Inc.: Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsVenus Concept Inc.: Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial Results
finanznachrichten.de - April 2 at 9:35 PM
VERO Stock Earnings: Venus Concept Misses EPS, Misses Revenue for Q4 2023VERO Stock Earnings: Venus Concept Misses EPS, Misses Revenue for Q4 2023
investorplace.com - April 1 at 1:03 PM
Venus Concept: Q4 Earnings SnapshotVenus Concept: Q4 Earnings Snapshot
houstonchronicle.com - April 1 at 9:42 AM
Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsVenus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial Results
globenewswire.com - April 1 at 7:00 AM
Venus Concept Inc.: Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing RulesVenus Concept Inc.: Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing Rules
finanznachrichten.de - March 26 at 2:33 AM
Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing RulesVenus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing Rules
globenewswire.com - March 25 at 7:30 AM
Venus Concept Launches "NEXThetics" ProgramVenus Concept Launches "NEXThetics" Program
stockhouse.com - March 13 at 10:30 AM
Venus Concept Launches “NEXThetics” ProgramVenus Concept Launches “NEXThetics” Program
globenewswire.com - March 12 at 4:05 PM
Venus Concept Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesVenus Concept Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
globenewswire.com - February 27 at 4:05 PM
Venus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesVenus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
globenewswire.com - February 23 at 8:00 AM
Nasdaq Surges 300 Points; NVIDIA Posts Strong ResultsNasdaq Surges 300 Points; NVIDIA Posts Strong Results
msn.com - February 23 at 1:09 AM
Venus Concept Announces CE Mark for Venus Versa Pro in EuropeVenus Concept Announces CE Mark for Venus Versa Pro in Europe
finance.yahoo.com - February 22 at 10:08 AM
Venus Concept Announces CE Mark for Venus Versa Pro in EuropeVenus Concept Announces CE Mark for Venus Versa Pro in Europe
globenewswire.com - February 22 at 7:30 AM
Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024
finance.yahoo.com - February 20 at 10:42 AM
Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024
globenewswire.com - February 20 at 7:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

LENSAR logo

LENSAR

NASDAQ:LNSR
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Nemaura Medical logo

Nemaura Medical

NASDAQ:NMRD
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
PAVmed logo

PAVmed

NASDAQ:PAVM
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Titan Medical logo

Titan Medical

NASDAQ:TMDI
Titan Medical, Inc. engages in the research and development of a computer-assisted robotic surgical technology for application in minimally invasive surgery (MIS). Its portfolio, the Enos™ system, is a robotic single access surgery with dual 3D and 2D definition vision systems, multi-articulating instruments, and a surgeon workstation. The company was founded on July 28, 2008 and is headquartered in Toronto, Canada.
Venus Concept logo

Venus Concept

NASDAQ:VERO
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.